|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
Exhibit Number
|
Description
|
99.1
|
18
January 2024 - “Holding(s) in Company”
|
GB00BMX86B70
|
HALEON PLC
|
UK
|
An acquisition or disposal of voting rights
|
GSK plc
|
BRENTFORD
|
United Kingdom
|
Name
|
City of registered office
|
Country of registered office
|
GSK
(No.1) Scottish Limited Partnership
|
Edinburgh
|
Scotland
|
GSK LP
Limited
|
London
|
England
|
GSK GP
1 Limited
|
Edinburgh
|
Scotland
|
Name
|
City
of registered office
|
Country
of registered office
|
Vidacos
Nominees Limited
|
London
|
England
|
17-Jan-2024
|
18-Jan-2024
|
|
%
of voting rights attached to shares (total of 8.A)
|
%
of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total
of both in % (8.A + 8.B)
|
Total
number of voting rights held in issuer
|
Resulting situation
on the date on which threshold was crossed or reached
|
4.170000
|
0.000000
|
4.170000
|
385320110
|
Position of
previous notification (if applicable)
|
7.420000
|
0.000000
|
7.420000
|
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
GB00BMX86B70
|
0
|
385320110
|
0.000000
|
4.170000
|
Sub
Total 8.A
|
385320110
|
4.170000%
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
2. Full chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held
starting with the ultimate controlling natural person or legal
entities (please add additional rows as necessary)
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
GSK plc
(Chain 1)
|
|
2.850000
|
|
2.850000%
|
GSK plc
(Chain 1)
|
GlaxoSmithKline
Holdings Limited (Chain 1)
|
2.850000
|
|
2.850000%
|
GSK plc
(Chain 1)
|
GlaxoSmithKline
Finance plc (Chain 1)
|
2.850000
|
|
2.850000%
|
GSK plc
(Chain 1)
|
Glaxo
Group Limited (Chain 1)
|
2.850000
|
|
2.850000%
|
GSK plc
(Chain 2)
|
|
1.330000
|
|
1.330000%
|
GSK plc
(Chain 2)
|
GSK LP
Limited (Chain 2)
|
1.330000
|
|
1.330000%
|
GSK plc
(Chain 2)
|
GSK GP
1 Limited (Chain 2)
|
1.330000
|
|
1.330000%
|
GSK plc
(Chain 2)
|
GSK
(No. 1) Scottish Limited Partnership (Chain 2)
|
1.330000
|
|
1.330000%
|
|
|
|
GSK plc is making this notification on behalf of itself and on
behalf of GSK LP Limited, GSK GP 1 Limited and GSK (No.1) Scottish
Limited Partnership.
This notification relates to the sale by GSK (No.1) Scottish
Limited Partnership (an entity indirectly wholly-owned by GSK plc)
of a portion of its interest in Haleon plc.
GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish
Limited Partnership.
GSK LP Limited is the sole limited partner of GSK (No.1) Scottish
Limited Partnership.Glaxo Group Limited and GSK (No.1) Scottish
Limited Partnership hold their shares in Haleon plc via a
custodian, Vidacos Nominees Limited, which holds the legal title to
those shares on their behalf pursuant to a custody
arrangement.
|
18-Jan-2024
|
London, England
|
|
|
HALEON PLC
(Registrant)
|
|
Date: January 18,
2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
Title:
|
Company
Secretary
|